SEARCH

SEARCH BY CITATION

References

  • Ashcroft T, Simpson JM, Timbrell V (1988). Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41 (4): 467470.
  • Belperio JA, Dy M, Burdick MD, Xue YY, Li K, Elias JA et al. (2002). Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 27 (4): 419427.
  • Bender AT, Beavo JA (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58 (3): 488520.
  • Boero S, Silvestri M, Sabatini F, Nachira A, Rossi GA (2006). Inhibition of human lung fibroblast functions by roflumilast N-oxide. Eur Respir J 662s: P3845 (abstract).
  • Boswell-Smith V, Page CP (2006). Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. Expert Opin Investig Drugs 15 (9): 11051113.
  • Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R (2001). In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297 (1): 280290.
  • Caramori G, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM et al. (2004). Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 45 (5): 477484.
  • Chaudhary NI, Schnapp A, Park JE (2006). Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 173 (7): 769776.
  • Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A (2007). Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572: 1222.
  • Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A (2006). IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12 (1): 99106.
  • Gensch E, Gallup M, Sucher A, Li D, Gebremichael A, Lemjabbar H et al. (2004). Tobacco smoke control of mucin production in lung cells requires oxygen radicals AP-1 and JNK. J Biol Chem 279 (37): 3908539093.
  • Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D et al. (2007). Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62 (12): 10811087.
  • Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J (2006). Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 7: 9.
  • Hatzelmann A, Schudt C (2001). Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297 (1): 267279.
  • Hemnes AR, Zaiman A, Champion HC (2008). PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol 294 (1): L24L33.
  • Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D et al. (2008). Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther 21: 616623.
  • Houslay MD, Schafer P, Zhang KY (2005). Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10 (22): 15031519.
  • Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R (2002). Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 83 (3): 111119.
  • Izikki M, Adnot S, Zadigue P, Barlier Mur AM, Maitre B, Raffestin B et al. (2007). Effect of roflumilast on hypoxia-and monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 294s: E1836 (abstract).
  • Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ et al. (2001). Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 158 (4): 14111422.
  • Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH et al. (2008). Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 14 (6): 633640.
  • Klar J, Sabatini F, Schatton E, Burgbacher B, Rossi GA, Hatzelmann A et al. (2007). Roflumilast N-oxide reduces human fibroblast function. Eur Respir J 544s: E3258 (abstract).
  • Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, Kim HJ et al. (2002). PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 26 (6): 694701.
  • Koshika T, Hirayama Y, Ohkubo Y, Mutoh S, Ishizaka A (2005). Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries. Eur J Pharmacol 515 (1–3): 169178.
  • Kumar RK, Herbert C, Thomas PS, Wollin L, Beume R, Yang M et al. (2003). Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 307 (1): 349355.
  • Le Quement C, Guenon I, Gillon JY, Valenca S, Cayron-Elizondo V, Lagente V et al. (2008). The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke. Br J Pharmacol 154: 12061215.
  • Lovgren AK, Jania LA, Hartney JM, Parsons KK, Audoly LP, Fitzgerald GA et al. (2006). COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 291 (2): L144L156.
  • Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G (2005). Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172 (7): 848853.
  • Mata M, Ruiz A, Cerda M, Martinez-Losa M, Cortijo J, Santangelo F et al. (2003). Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. Eur Respir J 22 (6): 900905.
  • Mata M, Sarria B, Buenestado A, Cortijo J, Cerda M, Morcillo EJ (2005). Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 60 (2): 144152.
  • Moeller A, Ask K, Warburton D, Gauldie J, Kolb M (2008). The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40 (3): 362382.
  • Moore BB, Hogaboam CM (2008). Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294 (2): L152L160.
  • Morcillo EJ, Cortijo J (2006). Mucus and MUC in asthma. Curr Opin Pulm Med 12 (1): 16.
  • Mutsaers SE, Foster ML, Chambers RC, Laurent GJ, McAnulty RJ (1998). Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol 18 (5): 611619.
  • Nakagome K, Dohi M, Okunishi K, Tanaka R, Miyazaki J, Yamamoto K (2006). In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax 61 (10): 886894.
  • O'Neill CA, Giri SN, Wang Q, Perricone MA, Hyde DM (1992). Effects of dibutyrylcyclic adenosine monophosphate on bleomycin-induced lung toxicity in hamsters. J Appl Toxicol 12 (2): 97111.
  • Ortiz LA, Champion HC, Lasky JA, Gambelli F, Gozal E, Hoyle GW et al. (2002). Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol 282 (6): L1209L1221.
  • Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P (1989). Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 170 (3): 655663.
  • Sanz MJ, Cortijo J, Morcillo EJ (2005). PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 106: 269297.
  • Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M et al. (2005). Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 (10): 28112821.
  • Serrano-Mollar A, Closa D, Cortijo J, Morcillo EJ, Prats N, Gironella M et al. (2002). P-selectin upregulation in bleomycin induced lung injury in rats: effect of N-acetyl-L-cysteine. Thorax 57 (7): 629634.
  • Takeyama K, Dabbagh K, Jeong Shim J, Dao-Pick T, Ueki IF, Nadel JA (2000). Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 164 (3): 15461552.
  • Tyner JW, Kim EY, Ide K, Pelletier MR, Roswit WT, Morton JD et al. (2006). Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest 116 (2): 309321.
  • Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC et al. (2000). SB239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279 (5): L895L902.
  • Weidenbach A, Braun C, Schwoebel F, Beume R, Marx D (2008). Therapeutic effect of various PDE4 inhibitors on cigarette smoke-induced pulmonary neutrophilia in mice. Am J Respir Crit Care Med 177: (abstract) A652.
  • Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R (2006). Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther 19 (5): 343352.
  • Zhen G, Park SW, Nguyenvu LT, Rodriguez MW, Barbeau R, Paquet AC et al. (2007). IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production. Am J Respir Cell Mol Biol 36 (2): 244253.